Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Lexaria Bioscience Corp
LEXX
Alternate Symbol(s):
LEXXW
Healthcare
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the...
bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:LEXX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(33)
•••
WakeUPP
X
View Profile
View Bullboard History
Comment by
WakeUPP
on Sep 08, 2021 10:30am
RE:RE:DehydraTECH-CBD relative to placebo
dude WOW Previous study on 10 RATS!!!!!!!!!!!!! MOST study on rats have zero effetct on people READ!!!!!!!!!!!!! The market KNOWS
(1)
•••
Yowza123
X
View Profile
View Bullboard History
Post by
Yowza123
on Sep 08, 2021 9:49am
Lexaria applies for FDA approved CBD with DehydraTECH
https://ir.lexariabioscience.com/news-events/press-releases/detail/149/lexaria-begins-investigational-new-drug-ind-enabling
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
posted Nov 14, 2024 9:00am by
NurExone Biologic Inc.
-
|
“We are honored by the EMA’s recognition of ExoPTEN through the Orphan Medicinal Product Designation, which significantly advances our ability to enter the European market and offers hope to those impacted by acute spinal cord injuries,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone. “This designation, together with the ...read more
(54)
•••
SkyLight8
X
View Profile
View Bullboard History
Post by
SkyLight8
on Sep 07, 2021 10:01pm
“Over the initial 24 hours, Lexaria’s 2021 hypertension prog
“Over the initial 24 hours, Lexaria’s 2021 hypertension program is now delivering blood pressure reduction results competitive with – and in some cases even superior to – established oral
...more
(54)
•••
SkyLight8
X
View Profile
View Bullboard History
Post by
SkyLight8
on Sep 07, 2021 9:54pm
the world will never get rid of oral drugs
DEHYDRATECH will make huge stride s with DATA on hand
(54)
•••
SkyLight8
X
View Profile
View Bullboard History
Post by
SkyLight8
on Sep 07, 2021 9:52pm
$LEXX $LEXX DehydraTECH is one of the world’s newest techn
$LEXX $LEXX DehydraTECH is one of the world’s newest technologies designed to improve the efficacy of orally administered bioactive molecules includes; anti-viral drugs, nicotine, cannabinoids non
...more
(54)
•••
SkyLight8
X
View Profile
View Bullboard History
Comment by
SkyLight8
on Sep 07, 2021 9:51pm
RE:DehydraTECH-CBD relative to placebo
Only thing that matters is FDA approved as did $GWPH
(1)
•••
Yowza123
X
View Profile
View Bullboard History
Comment by
Yowza123
on Sep 07, 2021 9:33pm
RE:DehydraTECH-CBD relative to placebo
Previous studies with Lexaria already showed DehydraTECH was vastly superior to CBD in other formats like this study from earlier this year: https://ir.lexariabioscience.com/news-events/press
...more
(2086)
•••
lscfa
X
View Profile
View Bullboard History
Post by
lscfa
on Sep 07, 2021 9:10pm
DehydraTECH-CBD relative to placebo
Maybe ordinary CBD is just as effective against placebo too. Why no comparison of DehydraTECH CBD to regular CBD?
(33)
•••
WakeUPP
X
View Profile
View Bullboard History
Comment by
WakeUPP
on Sep 07, 2021 3:41pm
RE:get ready for massive scale across USA
looooooooooooooool they have a deal with a penny stock promo comoany that sold 2 milion totla last year and lost 10s of millions do that have a deall with coors,molson,pepsi? nope how long
...more
(54)
•••
SkyLight8
X
View Profile
View Bullboard History
Post by
SkyLight8
on Sep 04, 2021 8:29pm
get ready for massive scale across USA
20$ stock easy DehydraTech on Twitter: "$LEXX already receiving royalty revenues throughout 7500 locations across #USA amazing margins and massive growth to come https://t.co/SPcvpTqxKI"
...more
(33)
•••
WakeUPP
X
View Profile
View Bullboard History
Comment by
WakeUPP
on Sep 02, 2021 12:58pm
RE:RE:DehydraTECH THC pouches to be sold in California
yay company has 2 million in total sales last year (its loseing10s of millions) so part of 2 milion has "dehyrdratech" and they pay a royalty on that for lexx it means NOTHING!!!!!!!!!!
...more
(5)
•••
Baust100
X
View Profile
View Bullboard History
Comment by
Baust100
on Sep 02, 2021 12:43pm
RE:DehydraTECH THC pouches to be sold in California
Here's an actual link that works.. Hill Street Beverage Company Inc Announces That its California Licensee, Cannadips, is in Production to Launch a THC Product Line Powered by DehydraTECH
...more
(33)
•••
WakeUPP
X
View Profile
View Bullboard History
Comment by
WakeUPP
on Aug 30, 2021 9:35am
RE:incredible human phase 2 coming
skylight?????????????? what happened ' a couple mmonths ago you DECLARED lexx wilould be $20 by Monday Nowi it is only $15? Theor human trilal ddidnt shoiw anything :( 10 rats!!!!!!!
(54)
•••
SkyLight8
X
View Profile
View Bullboard History
Post by
SkyLight8
on Aug 28, 2021 10:33am
incredible human phase 2 coming
get ready for 15$ also inredible antiviral developments busy september will blow the top off lexaria worldwide nice to see cannadips expanding their product line our 7 k stores
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Major Funding Secured! Company Closes First Round of Private Placement
This $10M Deal Could Reshape the Future of Global Creator Platforms
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.
Meet the Top 5 Best Online Brokerages in Canada
Gold, growth and sustainability in focus for this resource company
Coppernico Drills 19 Meters of 0.50% Copper in First 5 Holes and Applies for Additional Permits
New Gold and Copper Hotspot Identified – What’s Next for This Serbian Project?
Star Diamond Corporation Announces Third Quarter 2024 Results
Explained: The Psychology of Options Trading with Practical Tips
Geodrill Generates Revenue of $34.1M, a 13% Increase Compared to $30.3M for Q3-2023